CDC25 phosphatases control cell-cycle progression by dephosphorylating and activating cyclin-dependent kinases. CDC25B, one of the three members of this family in human cells, is thought to regulate initial mitotic events. CDC25B is an unstable protein whose proteasomal degradation is proposed to be controlled by b-TrCP. Here, we have investigated the regulation of CDC25B during mitosis, using time-lapse video microscopy. We found that CDC25B expression is high during early mitosis, and that its degradation occurs after the metaphase-anaphase transition and cyclin B1 destruction. We also show that CDC25B degradation after metaphase is dependent on the integrity of the KEN-box and RRKSE motifs that are located within the alternatively spliced B domain, and that the CDC25B2 splice variant, that lacks this domain, is stable during mitosis. Furthermore, we show that the N-terminal region of CDC25B, encompassing the B domain, undergoes major conformational changes during mitosis that can be monitored by intramolecular fluorescence resonance energy transfer variation of specific CDC25B biosensors. This study demonstrates that CDC25B splice variants have differential mitotic stabilities, a feature that is likely to have major consequences on the local control of cyclin-dependent kinase-cyclin activities during mitotic progression.
Introduction
In eukaryotic cells, the essential switch controlling entry into mitosis is the sudden activation of the cyclindependent kinase 1 (CDK1) associated with cyclin B1. This complex is kept inactive during interphase by phosphorylation on threonine 14 and tyrosine 15, and is dephosphorylated at the end of G 2 phase by the CDC25 dual-specificity phosphatases (Morgan, 1995) . In mammalian cells, there exists three CDC25 family members (CDC25A-C; for review, see Boutros et al., 2006) . It has been demonstrated that CDC25B cooperates with CDC25A to control entry into mitosis (Lindqvist et al., 2005) , and is the only CDC25 phosphatase shown to be required for re-entry in mitosis after DNA damage-induced G 2 cell-cycle arrest (van Vugt et al., 2004; van Vugt and Medema, 2005) . CDC25B phosphatase activity appears to be highly regulated by phosphorylation mechanisms. A number of regulatory kinases that activate or inhibit CDC25B have been identified (Baldin et al., 1997a (Baldin et al., , 2003 Bulavin et al., 2002; Theis-Febvre et al., 2003; Dutertre et al., 2004; Cazales et al. 2005; Manke et al., 2005; Mirey et al., 2005; Lemaire et al., 2006; Schmitt et al., 2006) (our unpublished data). These phosphorylation events modulate the catalytic activity, the interactions with regulatory partners such as 14-3-3 proteins, the localization and probably also the stability of CDC25B. CDC25B was shown to be a very unstable protein in interphase cells, with a half-life of less than 30 min in BHK cells arrested with hydroxyurea (Nishijima et al., 1997) . We also reported that CDC25B is degraded in a proteasome-dependent manner on phosphorylation by the CDK1-cyclin A complex (Baldin et al., 1997a) . These data suggest that the fine tuning of CDC25B levels might be an important aspect of the control of entry into mitosis. However, the exact timing of CDC25B accumulation during mitosis remains controversial, as CDC25B expression has been reported to be high in metaphase and decrease in anaphase in one study (Gabrielli et al., 1996) , and to accumulate until prophase and then disappear, in another study (Lindqvist et al., 2004) . Thus, the mechanisms that control CDC25B degradation during the cell cycle remain to be elucidated. The ubiquitination and subsequent degradation of a number of substrates has been shown to be dependent on the presence of a KEN box motif, composed of the sequence KEN(X)3N/D, that can be located either at the N-or C-terminus of proteins (Pfleger and Kirschner, 2000) . This box is recognized by the APC/C cdh1 E3 ligase. On arsenite treatment and G 2 /M arrest, the CDC25C phosphatase has been shown to be degraded in a KEN-boxdependent manner, as mutation within this region stabilized the protein (Chen et al., 2002) . It has been shown that CDC25A degradation during mitotic exit and early G 1 is mediated by the APC/C cdh1 E3 ligase and is dependent on a KEN-box motif located at the N terminus of the protein (Pfleger and Kirschner, 2000; Donzelli et al., 2002) . It has also been demonstrated that the SCF (Skp1/Cullin/F-box) E3-ligase was involved in the interphase degradation of CDC25A (Donzelli et al., 2002) . Thus, CDC25A degradation was proposed to be under the control of a dual regulatory mechanism (Donzelli et al., 2002) . The F-box protein that targets phosphorylated CDC25A for degradation by the SCF protein complex on DNA damage and during interphase was subsequently reported to be the b-TrCP protein (Busino et al., 2003; Jin et al., 2003) . A DSG binding motif within a (DSG(X) 4 S) consensus sequence present in a number of SCF substrates was identified on CDC25A, but recognition of CDC25A by b-TrCP was found to occur via a sequential phosphorylation of S76 by the CHK1 kinase and S82 by an unknown kinase (Jin et al., 2003; Donzelli et al., 2004) . More recently, it was found that human and Xenopus CDC25A also contain a previously undescribed nonphosphorylated DDG motif (DDGFXD) for b-TrCP binding (Kanemori et al., 2005) . The binding of b-TrCP to this motif is essential for CHK1-dependent ubiquitination and degradation of Xenopus CDC25A in Xenopus oocytes.
A DDG motif also exists in CDC25B and was found to be involved in its binding to b-TrCP, and to be required for the ubiquitination and degradation of human CDC25B when expressed in Xenopus eggs (Kanemori et al., 2005) . These findings led us to reexamine in detail the expression of CDC25B during the various phases of the cells progression through mitosis. We have investigated the regulation of CDC25B during mitosis using time-lapse video microscopy to analyse individual cells. We demonstrate that CDC25B accumulates in mitosis and is present until anaphase, after which it progressively disappears. We show that this mitotic degradation, which is accompanied by conformational changes, as visualized by fluorescence resonance energy transfer (FRET) experiments, requires both the integrity of the B domain, an alternately spliced 41 residue peptide that is absent in the CDC25B2 variant, and of the b-TrCP binding domain. We also identify within the B domain of CDC25B critical residues that are required for conformational change during mitosis and for its targeted degradation. Accordingly, we have found that CDC25B2 is very stable throughout mitosis. Interestingly, CDC25B2 has been reported to be overexpressed in a number of human tumours (Kristjansdottir and Rudolph, 2004) , raising the possibility of a link between the accumulation of a more stable variant of CDC25B and its deleterious effects on cell division.
Results

CDC25B levels vary during mitosis
To clarify the timing of CDC25B accumulation during progression into mitosis, we first examined the variation of its levels in cells synchronized by nocodazole block and release. As shown in Figure 1b , using U2OS cells expressing a HA-tagged version of CDC25B3, the most abundant splice variant (Baldin et al., 1997b) , we found by western blot analyses that CDC25B3 levels progressively decreased as cells progressed into and exited from mitosis. To investigate further this variation in a more physiological situation, we examined CDC25B endogenous levels in mitotic HeLa cells by immunofluorescence staining. We used a polyclonal antibody raised against a sequence that is present within the B domain (see Figure 1a) , one of the domains that are generated by alternative splicing of the CDC25B mRNA (Baldin et al., 1997b; Forrest et al., 1999) . This antibody is able to detect CDC25B1 and -3, but not the CDC25B2 splice variant. Cells were fixed and stained simultaneously with the antibody against CDC25B and with a cyclin B1 monoclonal antibody. As shown in Figure 1c , cyclin B1 was very rapidly degraded at the metaphase-anaphase transition, as already demonstrated by others (Clute and Pines, 1999 ). In contrast, the level of CDC25B was low during interphase and remained modestly detectable until late prophase ( Figure 1c ). From prometaphase, CDC25B levels increased, reaching a maximum at metaphase, and then progressively decreased during the later stages of mitosis and into G 1 phase. Strikingly, CDC25B was clearly still present at high levels in cells that were in anaphase while, at the same stage, cyclin-B1 was already completely degraded ( Figure 1c ).
Degradation of CDC25B occurs after metaphase
To investigate further CDC25B levels during mitosis, we used time-lapse video microscopy. We transiently expressed in HeLa cells a CDC25B3-YFP (yellow fluorescent protein) fusion protein, under the control of the cytomegalovirus (CMV) promoter. In addition, we co-expressed a histone H2B-HcRedT fusion protein to monitor in real time the separation of the sister chromatids at anaphase. Using these experimental conditions, we show again (Figure 2 ) that level of CDC25B3-YFP protein is maximal as the cells reach the metaphase-anaphase transition. Furthermore, by measuring the distance between the sister chromatids from the time of separation, we show that the normalized fluorescence intensity of CDC25B3-YFP starts to decrease when the cells are already engaged in anaphase (Figure 2 ). An mCerulean-CDC25B3 fusion protein was found to behave identically (data not shown), thus indicating that the position of the fluorescent protein moiety had no effect on the kinetics of CDC25B accumulation. However, these experiments are technically very limiting in terms of the deleterious effects reported for overexpression of full-length CDC25B (Gabrielli et al., 1996; Karlsson et al., 1999; Escalas et al., 2000) . Thus, to observe cells undergoing normal mitoses, it was essential to reduce the amount of transfected DNA and to select the rare cells that expressed very low levels of CDC25B, on which to perform time-lapse video microscopy, as exemplified by the cell shown in Figure 2 (lower panel).
Differential degradation of CDC25B splice variants during mitosis To circumvent the above-mentioned technical issues of CDC25B overexpression and to gain more insight into the expression of CDC25B under physiological conditions, we expressed enhanced yellow fluorescent protein (EYFP)-CDC25B fusion proteins under the control of the mouse minimal natural CDC25B promoter (Korner et al., 2001) . We found that this 1.011 kb promoter sequence was able to recapitulate cell cycle-regulated expression of a luciferase reporter gene in synchronized HeLa cells (data not shown), thus confirming its applicability in investigating the variation of CDC25B during mitosis. Using this minimal promoter, the Degradation of CDC25B during mitosis I Kieffer et al expression levels of EYFP-CDC25B after transient transfection were kept very low but nevertheless detectable, by live cell video microscopy. Figure 3a shows selected images of EYFP-CDC25B3 levels in a cell entering mitosis and dividing. These data are extracted from a video sequence available as Supplementary material (movie S1). As shown, after initial translocation from the cytoplasm to the nucleus on entry into mitosis, CDC25B3 accumulated and remained at a high level from metaphase until anaphase, after which the protein levels progressively decreased. Figure 3d shows the quantification (see Materials and methods) of EYFP-CDC25B3 levels relative to the metaphase-anaphase transition and represents the results obtained from eight independent mitotic cells. These observations confirm that CDC25B3 is downregulated after cells have passed the metaphaseanaphase transition. Using the same experimental strategy, we analysed the expression levels of the two splice variants EYPF-CDC25B1 and EYFP-CDC25B2 fusion proteins. As shown in Figures 3b and c, while EYFP-CDC25B1 was degraded similarly to EYFP-CDC25B3, EYFP-CDC25B2 level remained stable as cells progressed through mitosis and completed the division process. These observations indicate that in experimental conditions that recapitulate the physiological expression of endogenous CDC25B, the CDC25B1 and CDC25B3 proteins fused to EYFP are degraded after the metaphase-anaphase transition while CDC25B2 appears to be stable at this stage.
Since the CDC25B2 splice variant differs from CDC25B1 and CDC25B3 by the absence of the B domain (see Figure 1a ), these results suggested that this domain might be involved in regulating the degradation of CDC25B1 and CDC25B3 during mitosis.
Degradation of CDC25B during mitosis is dependent on the integrity of motifs within the B domain As illustrated in Figure 1a , domain B contains two charged residues clusters (RRKSE and EDKE) that could be exposed to the surface and involved in proteinprotein interaction, thus possibly regulating CDC25B degradation. With the EDKE cluster is associated a KEN motif that is conserved among the members of the CDC25 family, and that has been previously shown to be involved in the APC-dependent degradation of CDC25A (Chen et al., 2002; Donzelli et al., 2002) . To determine whether this KEN motif is involved in the mitotic degradation of CDC25B, we therefore investigated the behaviour of an EYFP-CDC25B3 construct carrying a mutation that consists of the change to alanine of all the charged residues of the EDKE cluster (construct pMP-EYFP-B3-EDKE*), expressed under the control of the mouse minimal natural CDC25B promoter. As shown in Figure 4a , this mutant protein was found to be stable during mitosis.
We also examined the effect on the degradation of CDC25B of the mutation of the second charged residues cluster, RRKSE. We also found that expression of the EYFP-CDC25B3 protein carrying the RRKSE/5A mutation under the control of the mouse minimal natural CDC25B promoter (construct pMP-EYFP-B3-RRKSE*) totally abolishes the mitotic degradation ( Figure 4b ).
These results indicate that the mitotic degradation of CDC25B is dependent on the integrity of both the KENbox and the RRKSE motifs present in the B domain and thus possibly on the APC/C cdh1 pathway.
Mitotic degradation of CDC25B also requires the integrity of the b-TRCP interaction DDG motif However, integrity of a b-TrCP interaction DDG motif (DDGFXD) has also been shown to be involved in the degradation of Xenopus CDC25A and human CDC25B expressed in Xenopus oocytes, and to participate, but Figure 2 Degradation of CDC25B during mitosis. HeLa cells were transiently co-transfected with CDC25B3-YFP and H2B-HcRedT plasmids and examined by time-lapse video microscopy. Normalized fluorescence intensity was determined as described in the Materials and methods (upper panel) . Distance between sister chromatids after the metaphase-anaphase transition was monitored in parallel (lower panel) and quantified. The timing of the experiment refers to the metaphase-anaphase transition.
Degradation of CDC25B during mitosis I Kieffer et al not to be essential, in the degradation of human CDC25A in the same system (Kanemori et al., 2005) . We therefore examined using the same strategy, the expression of a EYFP-CDC25B3 fusion protein carrying the previously described mutation of the DDG motif (Kanemori et al., 2005) that abolishes b-TrCP binding to CDC25B (mutant D270A, G273A and construct pMP-EYFP-B3-b-TrCP*). As shown in Figure 4c , this mutant protein remained stable on progression of the cells into mitosis.
These results indicate that, as suggested by previously published biochemical studies (Kanemori et al., 2005) , the mitotic degradation of CDC25B also requires the integrity of the DDG b-TrCP binding domain.
Conformational change of the N-terminal regulatory domain of CDC25B during mitosis
In parallel to this work, we examined whether the N-terminal regulatory domain (RD) of CDC25B, including the B domain, could undergo conformational changes during mitosis. To investigate this issue, we constructed molecular biosensors with the aim of monitoring intramolecular FRET to reveal the occurrence of conformational changes. These biosensors carry the region of the RD of CDC25B3 containing the sequences previously shown to be involved in its degradation during mitosis (RD161-390). This domain is surrounded by the mCerulean cyan fluorescent protein (CFP) and the citrine (YFP) fluorescent proteins, on the N-and C-terminal sides, respectively (Figure 5a ). These biosensors were transfected in HeLa cells and the FRET variation was examined in mitotic cells using time-lapse video microscopy. As shown in Figures 5b-d Degradation of CDC25B during mitosis I Kieffer et al this experiment is available as Supplementary data (movie S2). We observed a decrease in CFP fluorescence intensity concomitant with an increase in YFP fluorescence intensity (Figure 5c ), demonstrating a gain of FRET, which was further confirmed by the quantification of the YFP/CFP emission ratio (Figure 5d ).
These observations were further confirmed by monitoring several independent mitotic cells (Figure 5e ). However, we found that when the biosensor was restricted to residues 215-390 of the CDC25B3 RD, which lacks the B domain, no change in the emission ratio was observed during mitosis. Although the mean values of the emission ratios for the RD161-390 and the RD215-390 biosensors were significantly different, we cannot at this stage exclude the possibility that the difference in lengths of the two biosensors might contribute to the differences observed. Nevertheless, these results show that a conformational change of the CDC25B3 RD occurs during mitosis and that the B domain is also involved in the conformational change.
To elucidate further the role of the B domain in the conformational change of the CDC25B RD during mitosis, we used biosensors carrying mutations within this domain. Phosphorylation sites identified previously (S169, S178, S182-186-187; Bouche´, unpublished data) Mirey et al., 2005) , and charged residues (RRKSE, EDKE) mutant proteins were used in this assay. The relative abilities of these proteins to produce FRET variation during mitosis were examined and quantified in comparison with the wild-type protein. For each construct, a minimum of five mitotic cells was recorded, and their relative fluorescence quantified. As shown in Figure 5f , most of the mutant biosensors (S169A, S182-186-187A and EDKE*) displayed conformational changes during mitosis that were similar to those of wild-type CDC25B3 RD161-390. In some cases, the FRET variations were slightly modified, but not found to be statistically significant. For instance, we found that mutation of serine 178 (located in the RRKSE motif) to alanine had a partial effect on the ability of the RD161-390 CDC25B3 biosensor to change conformation and produce FRET variation during mitosis. In contrast, we found that the mutation RRKSE/5A (called RRKSE* in Figure 5f ) significantly reduced the FRET variation of the CDC25B3 RD161-390 biosensor during mitosis.
Together, these results indicate that the RRKSE motif located within the B domain is required for a conformational change that occurs within the RD of CDC25B during mitosis.
The RD161-390 domain recapitulates regulated mitotic degradation of CDC25B As the regulatory region of CDC25B comprised between AA161 and 390 was found to undergo conformational Comparison of the yellow/cyan emission ratio for the wild-type RD 161-390 and several mutants of the B domain transfected into HeLa cells and subjected to FRET analyses. Mutants contain single residue substitutions (S169A and S178A) or multiples substitutions (RRKSE to AAAAA, S182A-S1986A-S187A and EDKE to AAAA). Each result is the mean7s.e.m. of five independent experiments. * indicates a P-value between 0.01 and 0.05, obtained using an unpaired t-test. IMD, intensity-modulated display.
Degradation of CDC25B during mitosis I Kieffer et al change at mitosis, we examined whether this process was correlated with the mitotic degradation of CDC25B previously observed. To address this issue, we examined the degradation of the RD of CDC25B3 (RD161-390) by real-time video microscopy.
As shown in Figure 6a , with data from multiple independent determinations, the mCerulean-CDC25B3-RD161-390 fusion protein expressed in HeLa cells was consistently degraded as cells progressed through anaphase. This degradation pattern was similar to that observed for full length CDC25B3 (Figures 2 and 3) , thus indicating that the molecular determinants that are required for degradation of CDC25B3 during late mitosis, are conserved within this truncated version of the protein. To confirm using this system that the KEN motif is involved in the mitotic degradation of CDC25B, we monitored the behaviour of an mCerulean-CDC25B3 RD161-390 construct carrying the EDKE mutation (construct mCerulean EDKE*). Figure 6b shows that this mutant protein was consistently nondegraded.
We then also examined the effect of the RRKSE mutation on the degradation of the RD161-390 CDC25B protein (mCerulean RRKSE*). As reported in Figure 6c , we found that this mutant protein was not degraded after the metaphase-anaphase transition.
Within the RRKSE motif, mutation of serine 178 to alanine also led to the absence of mitotic degradation (Figure 6d) .
In control experiments where cells were co-transfected with the YFP-tagged wild type and mCerulean-tagged RRKSE mutant, we observed that the proteins were correctly degraded and not degraded at mitosis, respectively (data not shown).
Finally, we also expressed a mCerulean-CDC25B3 RD161-390 protein carrying the mutation of the DDG motif described above that abolishes b-TrCP binding (construct mCerulean b-TrCP*). As shown in Figure 6e , this protein was not degraded and remained stable during progression into mitosis.
Taken together, these results indicate that the mitotic degradation of the RD161-390 truncated protein recapitulates CDC25B3 degradation, and is dependent both on the integrity of motifs contained in the B domain and on b-TrCP binding. Degradation of CDC25B during mitosis I Kieffer et al
Discussion
When and how CDC25B is degraded is of major significance, since there is now increasing evidence that CDC25B expression is an essential parameter controlling the G 2 /M transition. There are a number of reports that CDC25B expression level are increased in human tumours (for review, see Kristjansdottir and Rudolph, 2004) . We and others have also shown that increased expression of CDC25B in tumour cells results in their increased sensitivity to genotoxic agents (Miyata et al., 2001; Bugler et al., 2006; Bansal and Lazo, personal communication) . Significantly, the overexpression of the CDC25B2 variant has been reported to be associated with high tumour grade and poor prognosis in several tumour types (Kristjansdottir and Rudolph, 2004) . It is therefore of significant interest to elucidate the mechanisms that regulate CDC25B expression and control its turnover during a normal cell cycle, and in response to genotoxic stress, as these mechanisms might be altered in several human pathological conditions. Previous reports on the kinetics of CDC25B accumulation during the cell cycle have been conflicting. Here, we clearly demonstrate by immunofluorescence staining and by time-lapse video microscopy that the CDC25B protein starts to accumulate late in G 2 phase, and becomes highly expressed in metaphase cells. We have demonstrated that the degradation of CDC25B only commences after sister chromatid separation, when the cells are already engaged in anaphase. These results are not a nonspecific effect of overexpression, since similar results were obtained both by monitoring CDC25B at the endogenous levels by immunofluorescence detection and by expression of CDC25B under the control of the murine minimal promoter that recapitulates the physiological expression of the phosphatase. Our results are in agreement with the initial observation published by Gabrielli et al. (1996) , who showed that CDC25B was abundant in mitotic HeLa cells. In disagreement with our findings, is the report that CDC25B levels rapidly decrease when cells reach prophase (Lindqvist et al., 2004) . One possible explanation for this discrepancy is the fact that in that study, the antibody used was raised against an internal peptide located in the N-terminal domain of CDC25B, within a region that can be masked after prophase, as our results on conformational change of the protein during mitosis would suggest. The degradation of CDC25B that we have documented after metaphase/anaphase concerns the CDC25B1 and CDC25B3, but not the CDC25B2 variant.
The CDC25B2 splice variant differs from CDC25B1 and CDC25B3 by the absence of the alternately spliced B domain (Baldin et al., 1997b) . Therefore, this observation raises a number of questions about its molecular basis and the identity of the determinants that control this degradation process. We have shown here that the degradation of CDC25B after the metaphaseanaphase transition is dependent of the integrity of the KEN-box and the RRKSE motif that are both present within the B domain. We have also shown here that the mitotic degradation of CDC25B requires the integrity of the b-TrCP binding motif, recently identified in CDC25A and CDC25B by Kanemori et al. (2005) .
The crystal structure of the CDC25B catalytic domain has been solved, but to date, no information is available on the three-dimensional structure of the RD of the CDC25 phosphatases. We have therefore used an original imaging approach to monitor in real time, CDC25B conformational changes that occur in cells undergoing mitosis. We have constructed biosensors harbouring on each side a GPF variant that can generate changes in FRET depending on their relative distance. CDC25B subdomains have been inserted between these two fluorescent proteins. Using this approach, we have been able to demonstrate the occurrence of a conformational change in the RD of CDC25B3 (amino acids 161-390) that occurs at the metaphase-anaphase transition. This conformational change is not observed when the RD is reduced to the 215-390 amino acid region, thus pointing to a possible involvement of the alternately spliced B domain. Indeed, we have shown that mutation of the RRKSE motif in the B domain is sufficient to abolish the conformational change of the RD169-390 CDC25B domain at the metaphase-anaphase transition. Other mutations within the 161-215 amino acid region, including S178A, had partial effects.
The mutation of the RRKSE cluster of charged residues had a major impact on both the ability of the protein to undergo conformational change and to be degraded after the metaphase-anaphase transition. The mutation of the KEN-box was also found to impair degradation of CDC25B at mitosis. We therefore propose that conformational change and post-metaphasic degradation of CDC25B are related events. We further speculate that post-translational modification and/or interaction with regulatory partners might affect the conformation of the CDC25B RD, thus rendering it accessible for interaction with b-TrCP and for its subsequent degradation by the proteasome pathway. However, the molecular basis for the requirement of the RRKSE and KEN motifs still remains unclear. We have recently found that S178 present in the RKKSE motif is a residue that is phosphorylated in vivo (Bouche´, unpublished data). Mutation of this residue had partial effects on conformational change occurring at mitosis and impaired the mitotic degradation of the RD169-390 CDC25B3 protein. It is therefore tempting to speculate that phosphorylation of S178 might participate in regulating this conformational change. Preliminary observations suggest that lysine 192 in the KEN motif might be one of the CDC25B ubiquitination sites. In Xenopus cdc25A, the ubiquitination efficiency seems to be determined not only by the efficiency of b-TrCP binding to the DDG motif but also by other events, such as the phosphorylation of dispersed sites (Kanemori et al., 2005) .
Thus, the phosphorylation of S178 and a dependent putative ubiquitination event might participate in the control of CDC25B degradation.
CDC25B is considered to be an unstable protein specifically required for early mitotic events, in particular those occurring at the centrosome level (Gabrielli et al., 1996; Dutertre et al., 2004) . The data we present here indicates that this is probably to be only a partial view of CDC25B function. CDC25B is indeed required together with CDC25A and CDC25C to trigger mitosis. However, with the reported evidence that CDC25B is present until late mitosis, it is likely that this phosphatase also plays a role in the timely regulated local activation of CDK-cyclin complexes later in mitosis. In line with this view, we propose a model to account for the regulation of CDC25B protein stability ( Figure 7 ). As we demonstrated previously, CDC25B remains very unstable before mitosis by phosphorylation by CDK1-cyclin A that targets it for proteasomedependent degradation (Baldin et al., 1997a) . We also showed that prior phosphorylation of CDC25B by CDK1-cyclin B was able to prevent CDK1-cyclin A-induced degradation (Cans et al., 1999) . Here, we report that CDC25B accumulates in mitotic cells, which might reflect a stabilizing effect due to CDK1-cyclin B phosphorylation. It is noteworthy that in contrast to CDC25C, CDC25B phosphatase activity per se is not enhanced by CDK1-cyclin B phosphorylation (Baldin et al., 2002) , suggesting that amplification of CDC25B biological activity might be achieved by an alternate mechanism involving its stabilization. Following the metaphase-anaphase transition, we have shown that CDC25B (except the CDC25B2 variant) is progressively degraded during the late stages of mitosis, suggesting that cyclin B degradation and decrease of the CDK1-cyclin B activity and/or additional events occurring at this time are able to target CDC25B to the proteasome pathway (Figure 7) . However, the identification of the molecular basis for these events requires further investigation.
We have reported here that a splice variant of CDC25B (CDC25B2) is not degraded during mitosis, as the other isoforms. These striking results should be considered in light of the evidence for a specific role for CDC25B upregulation in human tumours (for review, see Kristjansdottir and Rudolph, 2004) , and in particular upregulation of the CDC25B2 variant in aggressive non-Hodgkin's lymphomas and in colorectal carcinoma (Hernandez et al., 2000 (Hernandez et al., , 2001 . Given that CDC25B has been shown to have a role in the cellular response to DNA injury, abnormal expression of CDC25B through its global upregulation or through the expression of a stable variant, might favour inappropriate entry and progression of the cell through mitosis, thereby contributing to genetic instability of cancer cells.
Materials and methods
Plasmid constructs
The cdc25B murine promoter fragment described previously (GenBank accession no. AJ296019; Korner et al., 2001 ) was PCR amplified from murine genomic DNA with primers 5 0 -GGATTAATCTCAACTGCCCACTAGGTCC-3 0 (sense), which introduce an AseI restriction site and 5 0 -ATGCTA GCTGGGCCTGGGAGTGAGG-3 0 (antisense), which introduced a NheI restriction site. The murine-specific sequences are indicated in italics. The amplified product was then cloned into the AseI-NheI restriction sites of pEYFP-C1 vector (Clontech, Mountain View, CA, USA) instead of the CMV promoter, giving the pMP-EYFP-C1 plasmid. Human cDNA encoding CDC25B1, B2 and B3 were then fused to EYFP in the pMP-EYFP-C1 plasmid.
The RDs of CDC25B3 were amplified by PCR, adding 5 0 -EcoRI and 3 0 -BamHI sites to the sequence. These cDNA were then inserted in-frame into the corresponding sites of the pcDNA3.1 mCerulean-Citrine vector. To generate mutant constructs, fragments corresponding to residues 161-215 containing the desired mutations were synthesized (Genscript Corp., Piscataway, NJ, USA). For degradation experiments, the mCerulean constructs were generated by removing Citrine using BamHI and XbaI restriction sites and a Klenow treatment.
Antibodies and immunofluorescence
HeLa cells were seeded onto glass coverslips then fixed and permeabilized 24 h later as already described . DNA was visualized using diamidino-2-phenylindole. CDC25B rabbit polyclonal antibody (SE4198) against the B domain was described previously (Dutertre et al., 2004) . Cyclin B1 monoclonal antibody (GNS1) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary antibodies labelled with Alexa 488 or 594 (Molecular ProbeInvitrogen, Carlsbad, CA, USA) were used at the dilution of 1:800 for 1 h at room temperature. Images were acquired using the DM5000 microscope (Leica Microsystems, Wetzlar, Germany) fitted with a COOLsnapEs charge-coupled device (CCD) camera (Ropper Scientific, Tucson, AZ, USA) and subsequently processed using MetaMorph (Universal Image, Downingtown, PA, USA) and Photoshop software packages.
Cell culture and transfection HeLa cells and U2OS cells were grown as described previously . At 60-80% confluence, cells were transfected with lipofectine (Invitrogen, Carlsbad, CA, USA) using the manufacturer's instructions, and allowed to grow for 24 h before imaging.
CDC25B Figure 7 Working model. The variation of CDC25B protein levels during the cell cycle and in mitosis is schematically represented. Modification of CDC25B shape illustrates conformational changes occurring in the regulatory domain that correlate with degradation. The indicated effects of CDK1-cyclin A (CDK1/A) and CDK1-cyclin B (CDK1/B) on CDC25B degradation are based on our previous published data (Baldin et al., 1997a; Cans et al., 1999) . See text for details.
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Cell extracts and immunoblotting
At each time point after nocodazole bloc release, cells were lysed for 30 min on ice in lysis buffer (50 mM Tris, pH 7.5, 250 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 2 mM phenylmethylsulphonyl fluoride, 50 mM NaF, 2 mM sodium orthovanadate, 1% Triton X-100, 1% NP-40, 1 mM dithiothreitol, 50 nM Calpain inhibitor I and a cocktail of protease inhibitors (complete; Roche, Basel, Switzerland)). After centrifugation for 10 min at 10 000 g, 10mg of each lysate was denatured at 951C for 5 min, electrophoresed on a 10% Anderson sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel and analysed by western blotting using a monoclonal anti-HA (Eurogentec, Seraing, Belgium) (from Babco).
Cell imaging and FRET measurements
Cells were imaged on a Leica DMIRB (Leica Microsystems) with a 100 W mercury lamp. Images were acquired with a CoolSnapEs cooled CCD camera (Roper Scientific Princeton Instruments). Metamorph software was used for the control of the CCD camera. For visualizing real-time degradation and obtaining comparative quantitative analyses, all parameters were fixed, including the use of constant neutral density filtration to control intensity excitation, an integration time of 200 ms to optimize signal and minimize photobleaching, a Â 63 objective with a numerical aperture of 1.38 and a binning 2 Â 2 were used. Images were collected every 2 min. A region of interest (ROI) was drawn around each cell allowing change in cell shape during mitosis. Measurements of the average fluorescence intensity in the ROI were determined after which an average background fluorescence per pixel was subtracted at different time points. As fluorescence intensity varied among cells, results were presented as normalized fluorescence intensity by dividing all fluorescence intensities by the maximal fluorescence intensity, thereby setting the basal fluorescence intensity (before degradation) to 1. Degradation curves represent the normalized fluorescence intensity as a function of the time relative to metaphase-anaphase transition and correspond to the mean7s.e.m. of degradation curves that were obtained for at least five representative cells from three or more independent experiments.
For FRET experiments, fluorescence images were monitored in two channels, using a DMIRB filter cube wheel controlled by the MetaFluor image processing system (Universal Image) with a CFP channel (440721 nm excitation, 455DRLP, and 480730 nm emission) and a YFP FRET channel (440710 nm excitation, 455DRLP, 535726 nm emission). CFP and YFP images were acquired sequentially with an integration time of 150-200 ms without binning at 2 min intervals. Fluorescent images were background corrected by subtracting autofluorescence intensities corresponding to background values obtained in regions containing no cells. The average pixel intensity in the CFP and YFP FRET channels were measured within user-defined ROI surrounding cells. The ratios of yellow-to-cyan emission intensities were then calculated at different time. If mCerulean and YFP are in close proximity, excitation of mCerulean can stimulate emission from YFP. In our experiment, the uncertainties in FRET variation linked to the relative concentration of mCerulean and YFP and spectral crosstalk are minimized because both mCerulean and YFP are fused to the same protein to form a three component chimera whose conformation is sensitive to the biochemical environment (Miyawaki and Tsien, 2000) .
Statistical analyses on mutants were performed using the Prism (version 4.0) software package and the unpaired t-test.
